|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CPB2 |
Gene summary for CPB2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CPB2 | Gene ID | 1361 |
| Gene name | carboxypeptidase B2 | |
| Gene Alias | CPU | |
| Cytomap | 13q14.13 | |
| Gene Type | protein-coding | GO ID | GO:0001678 | UniProtAcc | A0A087WSY5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1361 | CPB2 | NAFLD1 | Human | Liver | NAFLD | 1.08e-04 | 8.12e-01 | -0.04 |
| 1361 | CPB2 | S42 | Human | Liver | HCC | 1.77e-02 | -6.20e-01 | -0.0103 |
| 1361 | CPB2 | S43 | Human | Liver | Cirrhotic | 1.22e-32 | -3.61e-01 | -0.0187 |
| 1361 | CPB2 | HCC1_Meng | Human | Liver | HCC | 9.11e-81 | -3.13e-01 | 0.0246 |
| 1361 | CPB2 | HCC2_Meng | Human | Liver | HCC | 8.90e-40 | -8.61e-01 | 0.0107 |
| 1361 | CPB2 | cirrhotic1 | Human | Liver | Cirrhotic | 1.46e-07 | -7.49e-02 | 0.0202 |
| 1361 | CPB2 | cirrhotic2 | Human | Liver | Cirrhotic | 4.30e-09 | 1.31e-01 | 0.0201 |
| 1361 | CPB2 | cirrhotic3 | Human | Liver | Cirrhotic | 2.33e-10 | -5.23e-01 | 0.0215 |
| 1361 | CPB2 | HCC1 | Human | Liver | HCC | 2.34e-12 | 5.74e+00 | 0.5336 |
| 1361 | CPB2 | HCC2 | Human | Liver | HCC | 6.23e-20 | 4.10e+00 | 0.5341 |
| 1361 | CPB2 | HCC5 | Human | Liver | HCC | 7.42e-12 | 1.23e+00 | 0.4932 |
| 1361 | CPB2 | Pt13.a | Human | Liver | HCC | 1.25e-02 | -1.83e-01 | 0.021 |
| 1361 | CPB2 | Pt13.b | Human | Liver | HCC | 4.42e-27 | -3.44e-01 | 0.0251 |
| 1361 | CPB2 | Pt13.c | Human | Liver | HCC | 1.53e-06 | -6.12e-01 | 0.0076 |
| 1361 | CPB2 | Pt14.a | Human | Liver | HCC | 4.37e-02 | -1.26e-01 | 0.0169 |
| 1361 | CPB2 | Pt14.b | Human | Liver | HCC | 2.82e-04 | -2.26e-01 | 0.018 |
| 1361 | CPB2 | Pt14.d | Human | Liver | HCC | 2.12e-06 | -3.72e-01 | 0.0143 |
| 1361 | CPB2 | S014 | Human | Liver | HCC | 1.86e-10 | 1.17e+00 | 0.2254 |
| 1361 | CPB2 | S015 | Human | Liver | HCC | 7.99e-10 | 1.38e+00 | 0.2375 |
| 1361 | CPB2 | S016 | Human | Liver | HCC | 1.08e-13 | 1.46e+00 | 0.2243 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00610417 | Liver | NAFLD | regulation of wound healing | 39/1882 | 134/18723 | 5.52e-10 | 1.28e-07 | 39 |
| GO:00420607 | Liver | NAFLD | wound healing | 84/1882 | 422/18723 | 6.56e-10 | 1.37e-07 | 84 |
| GO:0042730 | Liver | NAFLD | fibrinolysis | 15/1882 | 25/18723 | 1.26e-09 | 2.30e-07 | 15 |
| GO:0030195 | Liver | NAFLD | negative regulation of blood coagulation | 21/1882 | 49/18723 | 2.42e-09 | 4.05e-07 | 21 |
| GO:00094107 | Liver | NAFLD | response to xenobiotic stimulus | 88/1882 | 462/18723 | 2.53e-09 | 4.11e-07 | 88 |
| GO:1900047 | Liver | NAFLD | negative regulation of hemostasis | 21/1882 | 50/18723 | 3.78e-09 | 5.40e-07 | 21 |
| GO:0030193 | Liver | NAFLD | regulation of blood coagulation | 24/1882 | 66/18723 | 9.30e-09 | 1.26e-06 | 24 |
| GO:0050819 | Liver | NAFLD | negative regulation of coagulation | 21/1882 | 53/18723 | 1.33e-08 | 1.69e-06 | 21 |
| GO:1900046 | Liver | NAFLD | regulation of hemostasis | 24/1882 | 68/18723 | 1.84e-08 | 2.09e-06 | 24 |
| GO:0061045 | Liver | NAFLD | negative regulation of wound healing | 26/1882 | 78/18723 | 1.86e-08 | 2.09e-06 | 26 |
| GO:19030347 | Liver | NAFLD | regulation of response to wounding | 41/1882 | 167/18723 | 4.70e-08 | 4.58e-06 | 41 |
| GO:0050818 | Liver | NAFLD | regulation of coagulation | 24/1882 | 71/18723 | 4.80e-08 | 4.60e-06 | 24 |
| GO:00610087 | Liver | NAFLD | hepaticobiliary system development | 38/1882 | 150/18723 | 5.94e-08 | 5.42e-06 | 38 |
| GO:0051917 | Liver | NAFLD | regulation of fibrinolysis | 10/1882 | 14/18723 | 7.05e-08 | 6.34e-06 | 10 |
| GO:00075994 | Liver | NAFLD | hemostasis | 49/1882 | 222/18723 | 9.23e-08 | 7.59e-06 | 49 |
| GO:00018897 | Liver | NAFLD | liver development | 37/1882 | 147/18723 | 1.06e-07 | 8.12e-06 | 37 |
| GO:00075964 | Liver | NAFLD | blood coagulation | 48/1882 | 217/18723 | 1.16e-07 | 8.81e-06 | 48 |
| GO:00508174 | Liver | NAFLD | coagulation | 48/1882 | 222/18723 | 2.40e-07 | 1.61e-05 | 48 |
| GO:00458617 | Liver | NAFLD | negative regulation of proteolysis | 66/1882 | 351/18723 | 4.02e-07 | 2.58e-05 | 66 |
| GO:00903035 | Liver | NAFLD | positive regulation of wound healing | 20/1882 | 59/18723 | 5.91e-07 | 3.46e-05 | 20 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa04610 | Liver | NAFLD | Complement and coagulation cascades | 35/1043 | 86/8465 | 2.48e-11 | 2.04e-09 | 1.64e-09 | 35 |
| hsa046101 | Liver | NAFLD | Complement and coagulation cascades | 35/1043 | 86/8465 | 2.48e-11 | 2.04e-09 | 1.64e-09 | 35 |
| hsa046102 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
| hsa046103 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
| hsa046104 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
| hsa046105 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CPB2 | SNV | Missense_Mutation | rs368766293 | c.157N>T | p.Leu53Phe | p.L53F | Q96IY4 | protein_coding | tolerated(0.95) | probably_damaging(1) | TCGA-A7-A13E-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Targeted Molecular therapy | bevacizumab | PD |
| CPB2 | SNV | Missense_Mutation | c.1096C>G | p.Pro366Ala | p.P366A | Q96IY4 | protein_coding | tolerated(0.76) | probably_damaging(0.968) | TCGA-BH-A0BZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | CR | |
| CPB2 | SNV | Missense_Mutation | c.192N>C | p.Lys64Asn | p.K64N | Q96IY4 | protein_coding | tolerated(0.37) | probably_damaging(0.956) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CPB2 | SNV | Missense_Mutation | novel | c.731T>G | p.Phe244Cys | p.F244C | Q96IY4 | protein_coding | tolerated(0.19) | possibly_damaging(0.523) | TCGA-C5-A1MN-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| CPB2 | SNV | Missense_Mutation | novel | c.1192G>A | p.Glu398Lys | p.E398K | Q96IY4 | protein_coding | tolerated(0.07) | benign(0.005) | TCGA-C5-A2LZ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Unknown | Unknown | PD |
| CPB2 | SNV | Missense_Mutation | rs199530853 | c.232G>A | p.Asp78Asn | p.D78N | Q96IY4 | protein_coding | tolerated(0.69) | benign(0.003) | TCGA-DR-A0ZL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| CPB2 | SNV | Missense_Mutation | c.1067N>A | p.Gly356Asp | p.G356D | Q96IY4 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| CPB2 | SNV | Missense_Mutation | rs770303867 | c.325N>A | p.Asp109Asn | p.D109N | Q96IY4 | protein_coding | tolerated(0.14) | benign(0.042) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| CPB2 | SNV | Missense_Mutation | c.1067G>A | p.Gly356Asp | p.G356D | Q96IY4 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| CPB2 | SNV | Missense_Mutation | novel | c.491N>T | p.Ser164Phe | p.S164F | Q96IY4 | protein_coding | tolerated(0.06) | probably_damaging(0.997) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 1361 | CPB2 | DRUGGABLE GENOME, ENZYME, PROTEASE | UK-396082 | UK-396,082 | ||
| 1361 | CPB2 | DRUGGABLE GENOME, ENZYME, PROTEASE | inhibitor | 252166824 | ||
| 1361 | CPB2 | DRUGGABLE GENOME, ENZYME, PROTEASE | DS-1040 | |||
| 1361 | CPB2 | DRUGGABLE GENOME, ENZYME, PROTEASE | SAR-126119 | |||
| 1361 | CPB2 | DRUGGABLE GENOME, ENZYME, PROTEASE | inhibitor | 252166875 | ||
| 1361 | CPB2 | DRUGGABLE GENOME, ENZYME, PROTEASE | inhibitor | 252166857 | ||
| 1361 | CPB2 | DRUGGABLE GENOME, ENZYME, PROTEASE | inhibitor | 252166856 | ||
| 1361 | CPB2 | DRUGGABLE GENOME, ENZYME, PROTEASE | C5A | 14525995 | ||
| 1361 | CPB2 | DRUGGABLE GENOME, ENZYME, PROTEASE | SAR-104772 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |